Sales - Articles
26-Mar-2025
Selling medical devices to hospitals can be a lucrative yet challenging endeavor. With the healthcare industry growing and the demand for medical devices and medical equipment increasing, understanding how to sell medical devices effectively is crucial. In this guide, we’ll share key strategies for selling medical devices to hospitals, from identifying high-value facilities to proving your knowledge of their needs. Whether you’re selling medical equipment online or engaging with doctors and hospitals directly, these tips will help you navigate the complexities of the healthcare market.
Selling medical devices to hospitals can be a lucrative yet challenging endeavor. With the healthcare industry growing and the demand for medical devices and medical equipment increasing, unde…
Selling medical devices to hospitals can be a lucrative yet challenging endeavor. With the healthcare industry growing and the demand for medical devices and medical equipment increasing, unde…
Discover the ultimate guide to becoming a medical sales rep. Learn about different sales roles, including medical devices, pharmaceuticals, and healthcare software. Understand key responsibilities, essential skills, and how to meet industry compliance requirements. Find out how to gain relevant experience through internships, training programs, and sales roles. Learn the differences between inbound and outbound sales, and get tips on preparing for interviews to stand out in a competitive field. Explore the benefits of training programs like Medical Sales College, Medical Sales 101, and New To Medical Device Sales. With potential earnings of $68,000 to over $100,000 per year, this lucrative career offers substantial growth. Start your journey to building strong relationships with healthcare professionals and succeeding in the medtech industry today.
Discover the latest AI innovations transforming healthcare in 2025. From enhanced diagnostics and personalized patient care to operational efficiency, artificial intelligence is reshaping the medical landscape. Learn about top companies like Cleerly, Qure.ai, Owkin, Vitazi.ai, and Exscientia leading the charge with AI-powered solutions. This comprehensive overview also addresses critical challenges like data privacy, algorithm bias, and regulatory compliance. Alpha Sophia supports sales teams by making it easier to find doctors and engage early adopters, helping accelerate AI adoption across the healthcare industry. Find out how AI is redefining healthcare and how Alpha Sophia can help you reach the right audience faster.
AI in Healthcare: Key Innovations and 5 Companies to Watch in 2025…
AI in Healthcare: Key Innovations and 5 Companies to Watch in 2025…
Medical device sales is a dynamic and competitive industry that requires exceptional organization, strategic thinking, and strong relationship-building skills. With the global market projected to grow from approximately $518.46 billion in 2023 to $886.80 billion by 2032, the opportunities for success are significant—but so are the challenges.
Mastering territory management is a must for success in the competitive medical device industry. It’s the key to exceeding your sales targets, staying ahead of the competition, and building lasting relationships with healthcare professionals. By managing your territory effectively, you can focus on the right opportunities, boost sales, and consistently hit your targets. In this blog, we’ll share the top tips to help you organize and grow your sales territories effectively.
As part of our series focusing on how AI is transforming the pharmaceutical and life sciences industry, this article focuses on the realm of pharmaceutical sales. Here, we delve into how AI is currently being adopted in sales to enhance sales strategies, optimise marketing efforts, and improve customer engagement. We also explore potential future applications as well as the challenges and considerations associated with its implementation.
Artificial Intelligence (AI) has already proven its potential to revolutionise the world of pharmaceuticals, and although there’s still a way to go in terms of effectively implementing and using this technology to its full potential, it’s not going anywhere anytime soon. As part of our series focusing on how AI is transforming the pharmaceutical and life s…
Artificial Intelligence (AI) has already proven its potential to revolutionise the world of pharmaceuticals, and although there’s still a way to go in terms of effectively implementing and using this technology to its full potential, it’s not going anywhere anytime soon. As part of our series focusing on how AI is transforming the pharmaceutical and life s…
Transitioning from general sales to pharmaceutical sales can be an exciting career move that often offers better earning potential, professional growth, and the opportunity to work in a dynamic, science-driven industry where you can help improve the lives of patients across the globe.
Transitioning from general sales to pharmaceutical sales can be an exciting career move that often offers better earning potential, professional growth, and the opportunity to work in a dynamic, science-driven industry where you can help improve the lives of patients across the globe. Although achievable, breaking into the pharmaceutical sales field will require a strategic approach – along with a wealth of industry knowledge – to convince hiring managers that your sales experience is both valuable and transfe…
Transitioning from general sales to pharmaceutical sales can be an exciting career move that often offers better earning potential, professional growth, and the opportunity to work in a dynamic, science-driven industry where you can help improve the lives of patients across the globe. Although achievable, breaking into the pharmaceutical sales field will require a strategic approach – along with a wealth of industry knowledge – to convince hiring managers that your sales experience is both valuable and transfe…
Water for Injection is an essential component of pharmaceutical manufacturing, ensuring the safety and efficacy of products. From injectable drugs to vaccine production, WFI plays a critical role at every stage of the process, underscoring the need for precision, compliance, and innovation in its production and application.
Swjal Process is a leading pharmaceutical-grade water generation and distribution plant manufacturer in India.
The Role of Water for Injection (WFI) in Pharmaceutical Manufacturing Water for Injection (WFI) serves as a cornerstone of pharmaceutical manufacturing, where the highest standards of quality and purity are paramount. Its use spans the production of injectable drugs, vaccines, and other critical healthcare products, requiring utmost precision and control to e…
The Role of Water for Injection (WFI) in Pharmaceutical Manufacturing Water for Injection (WFI) serves as a cornerstone of pharmaceutical manufacturing, where the highest standards of quality and purity are paramount. Its use spans the production of injectable drugs, vaccines, and other critical healthcare products, requiring utmost precision and control to e…
We are delighted to announce that the second edition of our popular introductory guide: ‘Market access stakeholders and processes for medical devices in key European markets’ is now available. Our market access experts have updated the guide with European market insights for 2024/25, along with a new section covering the US market.
An introductory guide to market access stakeholders and processes for medical devices in key European markets and the USA In this introductory guide, our Global market access experts provide an overview of the commercial launch landscape for medical devices in the USA and key European healthcare systems. We highlight the differences between selected markets and provide a go-to guide for those looking to bring medical device innovations to the…
An introductory guide to market access stakeholders and processes for medical devices in key European markets and the USA In this introductory guide, our Global market access experts provide an overview of the commercial launch landscape for medical devices in the USA and key European healthcare systems. We highlight the differences between selected markets and provide a go-to guide for those looking to bring medical device innovations to the…
Calum Jones (Associate Director – Health Economics) shares his experience of speaking at the 2024 HTAi Annual Meeting. Calum participated in the panel discussion: ‘Surrogate Endpoints in Health Technology Assessment (HTA): From Trials to Economic Evaluations
Calum Jones (Associate Director – Health Economics) shares his experience of speaking at the 2024 HTAi Annual Meeting. Calum participated in the panel discussion: ‘Surrogate Endpoints in Health Technology Assessment (HTA): From Trials to Economic Evaluations’. On 18th June, I had the distinct pleasure of participating in an expert panel at the HTAi annual meeting held in the picturesque city of Seville, Spain. The session, titled ‘Surrogate Endpoints in Health Technology Assessment (HTA): From Trials to Economi…
Calum Jones (Associate Director – Health Economics) shares his experience of speaking at the 2024 HTAi Annual Meeting. Calum participated in the panel discussion: ‘Surrogate Endpoints in Health Technology Assessment (HTA): From Trials to Economic Evaluations’. On 18th June, I had the distinct pleasure of participating in an expert panel at the HTAi annual meeting held in the picturesque city of Seville, Spain. The session, titled ‘Surrogate Endpoints in Health Technology Assessment (HTA): From Trials to Economi…
03-May-2024
Hannah Palin (Director – Market Access) and Calum Jones (Associate Director – Health Economics) explore the landscape for economic evaluation in the US. They highlight important considerations for companies seeking to infiltrate this key market.
Health economic modelling is fundamental to market access, in both health technology assessment (HTA) and pre and post-launch engagement. It is of value globally, but holds particular importance in markets across Europe, the UK, and Canada, among others. Its application in the US, however, is less established. With a dedicated Health Economics Team, economic modelling is a key area in which Mtech Access support clients. Whilst there are variations in the approaches between HTA markets, we can see commonalities in the requirement for e…
Health economic modelling is fundamental to market access, in both health technology assessment (HTA) and pre and post-launch engagement. It is of value globally, but holds particular importance in markets across Europe, the UK, and Canada, among others. Its application in the US, however, is less established. With a dedicated Health Economics Team, economic modelling is a key area in which Mtech Access support clients. Whilst there are variations in the approaches between HTA markets, we can see commonalities in the requirement for e…
Specialists from across Mtech Access look at each of ISPOR’s top 10 HEOR trends for 2024–2025. Jump in as our experts give their hot take on each trend, sharing their perspectives on the topics in these areas (get ready – it’s a jam-packed read!).
Executive Summary Hayley Shoel and Abigail Beveridge, from our Medical Writing Team, outline what to expect from this paper in the below Executive Summary. In January 2024, ISPOR published their ‘2024–2025 Top HEOR Trends’ report, a horizon scanning publication that highlighted key trends affecting healthcare decision-making around the world. Since these trends resonate with our own research and activities here at Mtech Access, experts within our team have come together to share their perspectives on each of the t…
Executive Summary Hayley Shoel and Abigail Beveridge, from our Medical Writing Team, outline what to expect from this paper in the below Executive Summary. In January 2024, ISPOR published their ‘2024–2025 Top HEOR Trends’ report, a horizon scanning publication that highlighted key trends affecting healthcare decision-making around the world. Since these trends resonate with our own research and activities here at Mtech Access, experts within our team have come together to share their perspectives on each of the t…
Embarking on a systematic literature review is a critical step in evidence synthesis, providing a foundation for robust decision-making in the healthcare landscape. As with most things, there are ways to cut corners on systematic reviews. Sometimes there are true efficiencies to be made. Yet, all compromises have consequences.
In this article, we delve into 11 common problems that may arise when cost-cutting compromises the quality of your systematic literature review.
1. Choosing the wrong type of systematic review methodology Selecting the wrong type of methodology for your review can have profound implications. A robust, gold standard Cochrane methodology involves two reviewers at all stages of the review, to avoid bias in the identification and presentation of the evidence, and ensur…
1. Choosing the wrong type of systematic review methodology Selecting the wrong type of methodology for your review can have profound implications. A robust, gold standard Cochrane methodology involves two reviewers at all stages of the review, to avoid bias in the identification and presentation of the evidence, and ensur…
Specialised commissioning continues to be an issue of significance and uncertainty for both the NHS and industry. What do the latest reports of regional push back on the plans for devolution to Integrated Care Boards (ICBs) mean? Learn more about our upcoming webinar here.
For the past 2 years, Pharma, Medtech, and Diagnostic companies have identified the delegation of specialised commissioning to the new Integrated Care Boards (ICBs) as a key risk to their UK market access strategies. With its importance to income and the high risk of change devolution seems to promise, specialised commissioning is an obvious issue for providers of these products to place at the top of their risk logs. The devolution plans are also a risk for the NHS. Not least, because around two-thirds of the income of a…
For the past 2 years, Pharma, Medtech, and Diagnostic companies have identified the delegation of specialised commissioning to the new Integrated Care Boards (ICBs) as a key risk to their UK market access strategies. With its importance to income and the high risk of change devolution seems to promise, specialised commissioning is an obvious issue for providers of these products to place at the top of their risk logs. The devolution plans are also a risk for the NHS. Not least, because around two-thirds of the income of a…
We are delighted to announce that the second edition of our popular introductory guide: ‘Market access and reimbursement in key European markets’ is now available. Our market access experts have updated the reimbursement routes and added new market insights for 2023/24.
We are delighted to announce that the second edition of our popular introductory guide: ‘Market access and reimbursement in key European markets’ is now available. Our market access experts have updated the reimbursement routes and added new market insights for 2023/24. In this introductory guide, our Global market access experts present an overview of the reimbursement landscape in key European healthcare systems. We highlight the differences between key markets and provide a high-level guide for…
We are delighted to announce that the second edition of our popular introductory guide: ‘Market access and reimbursement in key European markets’ is now available. Our market access experts have updated the reimbursement routes and added new market insights for 2023/24. In this introductory guide, our Global market access experts present an overview of the reimbursement landscape in key European healthcare systems. We highlight the differences between key markets and provide a high-level guide for…
Maria Dimitrova (Consultant – HTA) and Samantha Gillard (Director – HTA) provide an overview of the EU Joint Clinical Assessment (JCA) and what it means for Pharma and Medical Device manufacturers launching new technologies from 2025.
What is the EU JCA? In January 2022, the European Parliament enacted a new EU Health Technology Assessment (HTA) Regulation, with the aim of standardising clinical assessment of medicines and high-risk medical devices across the EU and avoiding duplication of work. Currently, Pharma and Medtech manufacturers have to submit evidence individually in each of the 27 EU markets; the intention of the JCA is that at least some of the assessment can be done centrally. The JCA report will act as a universal information source for relative treatment effects, safety…
What is the EU JCA? In January 2022, the European Parliament enacted a new EU Health Technology Assessment (HTA) Regulation, with the aim of standardising clinical assessment of medicines and high-risk medical devices across the EU and avoiding duplication of work. Currently, Pharma and Medtech manufacturers have to submit evidence individually in each of the 27 EU markets; the intention of the JCA is that at least some of the assessment can be done centrally. The JCA report will act as a universal information source for relative treatment effects, safety…
DLL3 (DELTA-LIKE Protein 3) is encoded by the human gene and belongs to the Delta-Like protein family. It is a transmembrane protein involved in cell signaling, cell fate determination, and cell differentiation.
The Delta-Like protein family comprises ligands that interact with NOTCH receptors, crucial for cell development and differentiation. DLL3 plays a pivotal role in neurogenesis, contributing to the generation of neurons during embryonic development.
DLL3 has garnered significant interest in cancer research, particularly in certain types of cancer. Elevated DLL3 expression has been detected in some small cell lung cancer (SCLC) and other neuroendocrine tumors. As a result, targeted treatment approaches have been developed to inhibit DLL3, providing a potential treatment strategy for these aggressive cancers.
The biotech industry is a large and growing field with many opportunities for those who want to pursue it professionally. The growth of this industry has been rapid in recent years, with more than 200 new products being marketed every year. In this article, we will look at the current trends in the industry and discuss how they affect marketers and consumers.
What is Biotechnology? Biotechnology is the application of biological processes and materials, including biochemistry, microbiology and molecular biology. Nobel-prize-winning chemist George Wald coined the term in 1949. Biotechnology is not the same as traditional biochemistry: it encompasses a diverse range of techniques we can use for industrial processing and research purposes. For example, it includes processes such as recombin…
What is Biotechnology? Biotechnology is the application of biological processes and materials, including biochemistry, microbiology and molecular biology. Nobel-prize-winning chemist George Wald coined the term in 1949. Biotechnology is not the same as traditional biochemistry: it encompasses a diverse range of techniques we can use for industrial processing and research purposes. For example, it includes processes such as recombin…
The biotech industry is a large and growing field with many opportunities for those who want to pursue it professionally. The growth of this industry has been rapid in recent years, with more than 200 new products being marketed every year. In this article, we will look at the current trends in the industry and discuss how they affect marketers and consumers.
What is Biotechnology? Biotechnology is the application of biological processes and materials, including biochemistry, microbiology and molecular biology. Nobel-prize-winning chemist George Wald coined the term in 1949. Biotechnology is not the same as traditional biochemistry: it encompasses a diverse range of techniques we can use for industrial processing and research purposes. For example, it includes processes such as recombin…
What is Biotechnology? Biotechnology is the application of biological processes and materials, including biochemistry, microbiology and molecular biology. Nobel-prize-winning chemist George Wald coined the term in 1949. Biotechnology is not the same as traditional biochemistry: it encompasses a diverse range of techniques we can use for industrial processing and research purposes. For example, it includes processes such as recombin…
Medicines are becoming ever more complex in response to growth in personalised treatments and the development of a wide range of therapeutics to address less common conditions or rare diseases
by Kelly Doering, Sr Director, Industry Marketing, Pharma, AspenTech Medicines are becoming ever more complex in response to growth in personalised treatments and the development of a wide range of therapeutics to address less common conditions or rare diseases. Examples of the latter include small molecules linked to large, perhaps conjugated to a chemotoxic agent for targeted cancer treatment; peptides linked to peptides; oligos linked to molecules that allow for better cell permeability; and lipid-encapsulated molecules that prevent degradation. But it is the market for more personalised medication…
by Kelly Doering, Sr Director, Industry Marketing, Pharma, AspenTech Medicines are becoming ever more complex in response to growth in personalised treatments and the development of a wide range of therapeutics to address less common conditions or rare diseases. Examples of the latter include small molecules linked to large, perhaps conjugated to a chemotoxic agent for targeted cancer treatment; peptides linked to peptides; oligos linked to molecules that allow for better cell permeability; and lipid-encapsulated molecules that prevent degradation. But it is the market for more personalised medication…
Two laboratory relocation specialists have joined forces to offer customers a seamless approach to moving samples alongside other elements of a lab.
Two laboratory relocation specialists have joined forces to offer customers a seamless approach to moving samples alongside other elements of a lab. Lab removal firm Aport and sample logistics company Biocair have teamed up to bring combined expertise to their customers’ projects. The collaboration offers simplified project management and a single point of contact. The two firms will mark the new venture with a free webinar detailing 10 steps to follow when relocating a lab, taking place on Thursday 10th June. Commercial director of Aport, Tom Wickstead, said the partnership set new standards for the industry. “We’ve worked with Biocair o…
Two laboratory relocation specialists have joined forces to offer customers a seamless approach to moving samples alongside other elements of a lab. Lab removal firm Aport and sample logistics company Biocair have teamed up to bring combined expertise to their customers’ projects. The collaboration offers simplified project management and a single point of contact. The two firms will mark the new venture with a free webinar detailing 10 steps to follow when relocating a lab, taking place on Thursday 10th June. Commercial director of Aport, Tom Wickstead, said the partnership set new standards for the industry. “We’ve worked with Biocair o…
